Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more
Author(s): Gregory Lewis Added: 3 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more
Research Area(s) / Expertise: Job title: Medical Director
Job title: Reader in Cardiovascular Physiology
Personal History Dr Jamie O'Driscoll is based in Canterbury, UK where he holds the position of Reader in Cardiovascular Physiology at Canterbury Christ Church University. Academic History Dr Jamie O'Driscoll, BSc (Hons), MSc (Hons), CertEd, PhD, graduated with a 1st class honours in Sport Science from Brunel University, where he went on to earn a distinction in his MSc in Health and… View more